Published in Neurology on July 06, 2011
The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve (2013) 2.47
Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One (2014) 2.43
Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS. Neurology (2014) 1.79
The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve (2013) 1.63
Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol (2016) 1.53
The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve (2013) 1.48
Percent-predicted 6-minute walk distance in duchenne muscular dystrophy to account for maturational influences. PLoS Curr (2012) 1.48
Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve (2014) 1.41
24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS One (2013) 1.34
Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol (2012) 1.31
New treatments for mitochondrial disease-no time to drop our standards. Nat Rev Neurol (2013) 1.26
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology (2012) 1.17
6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes. PLoS One (2014) 1.11
Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study. PLoS One (2016) 1.06
Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to 12 years. PLoS One (2013) 0.97
Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscul Disord (2013) 0.93
Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial. Orphanet J Rare Dis (2014) 0.90
Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. EMBO Mol Med (2015) 0.89
Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases? EPMA J (2013) 0.89
The 6 minute walk test and performance of upper limb in ambulant duchenne muscular dystrophy boys. PLoS Curr (2014) 0.86
Lung function monitoring in patients with duchenne muscular dystrophy on steroid therapy. BMC Res Notes (2012) 0.84
One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development. Pediatr Neurol (2014) 0.83
The role of the neuromuscular medicine and physiatry specialists in the multidisciplinary management of neuromuscular disease. Phys Med Rehabil Clin N Am (2012) 0.82
The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry (2015) 0.80
Quantitative muscle ultrasound detects disease progression in Duchenne muscular dystrophy. Ann Neurol (2017) 0.79
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. Neuromuscul Disord (2016) 0.77
DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology (2016) 0.77
Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study. PLoS One (2016) 0.77
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study. PLoS One (2016) 0.76
Age-related longitudinal changes in metabolic energy expenditure during walking in boys with Duchenne muscular dystrophy. PLoS One (2014) 0.76
The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis (2017) 0.75
Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies. Sci Rep (2016) 0.75
Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial. Trials (2016) 0.75
Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy. PLoS One (2016) 0.75
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study. Neuromuscul Disord (2016) 0.75
Developing a Natural History Progression Model for Duchenne Muscular Dystrophy using the Six Minute Walk Test. CPT Pharmacometrics Syst Pharmacol (2017) 0.75
Electrical impedance myography for assessment of Duchenne muscular dystrophy. Ann Neurol (2017) 0.75
Quantifying fat replacement of muscle by quantitative MRI in muscular dystrophy. J Neurol (2017) 0.75
Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science (2010) 6.67
Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet (2001) 5.09
Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature (1987) 4.59
Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature (1995) 4.18
The neutrophil as a cellular source of chemokines. Immunol Rev (2000) 4.09
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med (1999) 3.76
An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region. Nature (1989) 3.75
SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology (2010) 3.37
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
The O2- -forming NADPH oxidase of the phagocytes: nature, mechanisms of activation and function. Biochim Biophys Acta (1986) 3.32
Mutations of SURF-1 in Leigh disease associated with cytochrome c oxidase deficiency. Am J Hum Genet (1998) 3.08
Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8. J Exp Med (1991) 2.96
Paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients: P wave duration and dispersion analysis. Eur Rev Med Pharmacol Sci (2015) 2.86
The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol (2000) 2.76
Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet (1998) 2.72
White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry (2002) 2.72
Electronic nose analysis of urine samples containing blood. Physiol Meas (1999) 2.68
Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet (2001) 2.66
Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology (2008) 2.57
Clinical and molecular findings in children with complex I deficiency. Biochim Biophys Acta (2004) 2.52
Evaluation of three-dimensional finite element-based deformable registration of pre- and intraoperative prostate imaging. Med Phys (2001) 2.50
MELAS: clinical features, biochemistry, and molecular genetics. Ann Neurol (1992) 2.48
RelB is essential for the development of myeloid-related CD8alpha- dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells. Immunity (1998) 2.42
Coding sequence and growth regulation of the human vimentin gene. Mol Cell Biol (1986) 2.34
Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study. Neurology (2009) 2.33
The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol (1990) 2.29
Enzymatic basis of metabolic stimulation in leucocytes during phagocytosis: the role of activated NADPH oxidase. Arch Biochem Biophys (1971) 2.27
Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology (2001) 2.24
Low-frequency positive-pressure ventilation with extracorporeal CO2 removal in severe acute respiratory failure. JAMA (1986) 2.24
Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat Genet (1996) 2.22
Modified perineal stapled rectal resection with Contour Transtar for full-thickness rectal prolapse. Colorectal Dis (2009) 2.20
Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord (2009) 2.13
Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology (2006) 2.11
Thiophosphorylation of U1-70K protein inhibits pre-mRNA splicing. Nature (1993) 2.09
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst (2000) 2.06
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology (2004) 2.04
Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology (2010) 2.03
Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler (2001) 2.03
The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med (2000) 2.02
Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (2001) 2.00
Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nat Genet (2001) 2.00
GJA12 mutations are a rare cause of Pelizaeus-Merzbacher-like disease. Neurology (2007) 1.93
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol (2011) 1.93
[Use of statistics in occupational medicine. Analysis of papers presented at the national congresses of the Italian Society of Occupational Medicine and Industrial Hygiene]. Med Lav (1993) 1.92
Myotonic dystrophy: evidence for a possible dominant-negative RNA mutation. Hum Mol Genet (1995) 1.89
Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol (2000) 1.88
Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci (2003) 1.87
The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia (2000) 1.86
Different thermostabilities of FLP and Cre recombinases: implications for applied site-specific recombination. Nucleic Acids Res (1996) 1.86
Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol (1997) 1.85
Cognitive and psychosocial features of childhood and juvenile MS. Neurology (2008) 1.85
Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol (2010) 1.85
Oligophrenin 1 mutations frequently cause X-linked mental retardation with cerebellar hypoplasia. Neurology (2005) 1.85
Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology (2010) 1.85
Paraplegia following coeliac plexus block. Pain (1993) 1.85
Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Ann Neurol (2000) 1.84